# UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

> **NCT00072267** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto**

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** 7-hydroxystaurosporine
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00072267
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2005-04
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2015-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072267, "UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00072267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*